摘要
Summary:In various autoimmune diseases,Galecin-9(Gal-9)has been shown to regulate the T-cell balance by decreasing Th1 and Th17,while increasing the number of regulatory T cells(Tregs).However,the role of Gal-9 in the patients with acute coronary syndrome(ACS)and chronic kidney disease(CKD)remains unclear.This study aims to measure the Gal-9 levels in serum and peripheral blood mononuclear cells(PBMCs)in patients with ACS plus CKD and examine their clinical implication.The serum levels of Gal-9 were determined by enzyme linked immunosorbent assay(ELISA),the expression levels of Gal-9,Tim-3,and Foxp3 mRNA in PBMCs were detected by real-time reverse transcription-polymerase chain reaction(RT-PCR),and the expression of Gal-9 on the surface of PBMCs and in PBMCs was analyzed by flow cytometry.Furthermore,the correlation of serum Gal-9 levels with anthropometric and biochemical variables in patients with ACS plus CKD was analyzed.The lowest levels of Gal-9 in serum and PBMCs were found in the only ACS group,followed by the ACS+CKD group,and the normal coronary artery(NCA)group,.respectively.Serum Gal-9 levels were increased along with the progression of glomerular filtration rate(GFR)categories of G1 to G4.Additionally,serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein(hs-CRP),estimated GFR(eGFR),and lipoprotein(a),but positively with creatinine,age,osmotic pressure,and blood urea nitrogen(BUN).Notably,serum Gal-9 was independently associated with hs-CRP,osmotic pressure,and lipoprotein(a).Furthermore,serum Gal-9 levels were elevated in patients with type 2 diabetes(T2DM)and impaired glucose tolerance(IGT)in ACS group.It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD,and hs-CRP,eGFR,osmotic pressure and T2DM may have an influence on serum Gal-9 levels.
基金
This project was supported by grants from National Natural Science Foundation of China(No.81270354)
Natural Science for Youth Foundation(No.81300213).
